Stifel reiterates Dyne Therapeutics stock rating on trial data
Covered in this story
What has happened since
- Dyne Therapeutics Inc is down 4.8% since this was published, 5 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Stifel’s $37 target on $DYN is on the record and being tracked to Sep 2027 (12-month default), scored on the close that day.
Stifel’s track record →Analyst targets on Dyne Therapeutics Inc
- Jefferies: $16.2 → $50 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $DYN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Dyne Therapeutics Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.